SCHEMBL4747720

SCHEMBL4747720

Cc1cn([C@H]2C[C@H](F)[C@@H](COP(=O)(O)O)O2)c(=O)[nH]c1=O

nearest known ligand 0.77

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TK1 P04183 4/20 0.77
POLB P06746 2/20 0.63
TYMS P04818 1/20 0.62
POLA1 P09884 1/20 0.58
POLD1 P28340 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30583236 1.00 TK1 (0.77) TK1POLBTYMSPOLA1POLD1
SCHEMBL7192376 0.90 POLB (0.73) TK1POLBTYMSPOLA1POLD1
Thymidine Monophosphate SCHEMBL18785041 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL2037921 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL16092807 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL7876022 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL8366987 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL16280929 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL3984895 0.88 POLB (0.80) TK1POLBTYMS
Thymidine Monophosphate SCHEMBL21257 0.88 POLB (0.80) TK1POLBTYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0791056-B1 LIPID-CLEAVAGE ENZYME COMPLEX HEIDELBERG PHARMA GMBH (DE) 2005-03-30 EP claimed
US-20030082167-A1 Lapid cleavage enzyme HEIDELBERG PHARMA HOLDING GMBH 2003-05-01 US claimed
US-5563257-A Phospholipid derivatives of nucleosides BOEHRINGER MANNHEIM GMBH (DE) 1996-10-08 US claimed
EP-0545966-B1 NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PREPARATION AND THEIR USE AS ANTIVIRAL DRUGS BOEHRINGER MANNHEIM GMBH (DE) 1994-11-23 EP claimed
US-20080249066-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS ARDEA BIOSCIENCES, INC. (US) 2008-10-09 US disclosed
WO-2008118879-A2 ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS ARDEA BIOSCIENCES, INC. (US) 2008-10-02 WO disclosed
US-7176011-B2 Lipid cleavage enzyme HEIDELBERG PHARMA AG (DE) 2007-02-13 US disclosed
EP-0791056-B1 LIPID-CLEAVAGE ENZYME COMPLEX HEIDELBERG PHARMA GMBH (DE) 2005-03-30 EP disclosed
US-20030082167-A1 Lapid cleavage enzyme HEIDELBERG PHARMA HOLDING GMBH 2003-05-01 US disclosed
US-20020122817-A1 SOLID INSTANT-RELEASE FORMS OF ADMINISTRATION AND PROCESS FOR PRODUCING THE SAME HEIDELBERG PHARMA HOLDING GMBH (DE) 2002-09-05 US disclosed
US-20020106363-A1 LIPID CLEAVAGE ENZYME HEIDELBERG PHARMA HOLDING GMBH (DE) 2002-08-08 US disclosed
US-6372725-B1 VIRICIDES, ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION HEIDELBERG PHARMA HOLDING GMBH (DE) 2002-04-16 US disclosed
EP-0817790-B1 SPECIFIC LIPID CONJUGATES OF NUCLEOSIDE DIPHOSPHATES AND THEIR USE AS DRUGS HEIDELBERG PHARMA HOLDING GMBH (DE) 2001-11-14 EP disclosed
US-5756711-A Phospholipid derivatives of nucleosides and their use as anti-viral medicaments BOEHRINGER MANNHEIM GMBH (DE) 1998-05-26 US disclosed
EP-0791056-A2 LIPID-SPLITTING ENZYME Roche Diagnostics GmbH (DE) 1997-08-27 EP disclosed
US-5563257-A Phospholipid derivatives of nucleosides BOEHRINGER MANNHEIM GMBH (DE) 1996-10-08 US disclosed
WO-1996015234-A2 LIPID-SPLITTING ENZYME BOEHRINGER MANNHEIM GMBH (DE) 1996-05-23 WO disclosed
US-5153180-A Used for treating aids BURROUGHS WELLCOME CO. 1992-10-06 US disclosed
US-4963662-A Fluorinated nucleosides and method for treating retrovirus infections therewith AKADEMIE DER WISSENSCHAFTEN DER DDR (DD) 1990-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249066-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS PNP, TYMP, MTAP TK1 114/4885POLB 46/4885TYMS 17/4885
US-20030082167-A1 Lapid cleavage enzyme LAP3, NAALAD2, ENGASE TK1 975/4885POLB 3644/4885TYMS 2654/4885
US-20020122817-A1 SOLID INSTANT-RELEASE FORMS OF ADMINISTRATION AND PROCESS FOR PRODUCING THE SAME ADAR, PAICS, GART TK1 17/4885POLB 2676/4885TYMS 212/4885
US-20020106363-A1 LIPID CLEAVAGE ENZYME SMPD1, MMEL1, ENGASE TK1 689/4885POLB 2942/4885TYMS 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.